Publications by authors named "Kaoru Funabashi"

Claim this Profile
A
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Isao Miyazaki, Igor Odintsov, Keiji Ishida, Allan J W Lui, Masanori Kato, Kaoru Funabashi

Nat Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Isao Miyazaki, Igor Odintsov, Keiji Ishida, Allan J W Lui, Masanori Kato, Kaoru Funabashi

Nat Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa, Atsushi Hirano, Hideki Kazuno, Kaoru Funabashi

ACS Med Chem Lett· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
Kei Oguchi, Hikari Araki, Shingo Tsuji, Masayuki Nakamura, Akihiro Miura, Kaoru Funabashi

Cancer Sci· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito, Hiroaki Ochiiwa, Yayoi Fujioka, Kaoru Funabashi

Cancer Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant Mutations.
Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Kaoru Funabashi

Mol Cancer Res· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.
Hiroki Irie, Kimihiro Ito, Yayoi Fujioka, Kei Oguchi, Akio Fujioka, Kaoru Funabashi

Mol Cancer Ther· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.
Takao Uno, Yuichi Kawai, Satoshi Yamashita, Hiromi Oshiumi, Chihoko Yoshimura, Kaoru Funabashi

J Med Chem· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation.
Tomoko Sunami, Noel Byrne, Ronald E Diehl, Kaoru Funabashi, Dawn L Hall

J Biol Chem· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis